Fierce Pharma June 30, 2022
Increasingly, cell and gene therapies are changing the treatment landscape for various cancers and rare diseases. As the pricey treatments become more popular, will their costs shock the healthcare system, or will biopharma companies and payers come together to ensure affordable access?
During a panel discussion for the Fierce Biotech Next Gen virtual event, experts representing a range of industry leaders discussed the important topic. While the experts noted several promising trends in access talks, there’s potential for hazard ahead, one warned.
In the U.S., Novartis has the most experience marketing a gene therapy after its 2019 FDA approval for spinal muscular atrophy treatment (SMA) Zolgensma. Despite the drug’s $2.1 million price tag in the U.S., cost...
Today's Sponsors
Today's Sponsor